Great job everyone! 👏👏👏

Here we are investigating neoadjuvant encorafinib + cetuximab in locally advanced BRAF-mutated colon cancer c/w chemotherapy. Important to find new strategies for this poor prognosis population 👍💪🏻Janet graham

🎉🎉🎉

Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis ➡️ doi.org/10.1093/bjs/zn… This systematic review and meta-analysis of seven studies involving 2120 patients with locally advanced colon cancer found that

And we’re off!!! Testing neoadjuvant EC in BRAF-mut locally advanced colon cancer. 🙏🏽 Sonali Dasgupta and team Velindre University NHS Trust

🚨 #LowerGIcancer highlights from #ASCO24 🚨 Prof. Jenny Seligmann & Dr Dominik Paul Modest share their views on new data from #COLLISION & #TRANSMET trials presented at the congress. ⬇️🎥⬇️ #MedEd #ASCOhighlights #CRCSM #LowerGI

Congratulations to the FOxTROT & ARIEL radiology support team for collecting 2 prestigious awards as top 20 presenters at the ESGAR, Gothenburg. 1st-time winner Dr James Platt delivered an analysis of the accuracy of CT scans for staging bowel cancer, funded by YCR.

Congratulations to Dr Niki Christou and the team in France who have randomised their first FOxTROT 2 participant! 🎉🎉🎉 I'm also pleased to announce that our Indian team have a total of 4 randomised participants! An amazing effort by both teams. 👏👏👏

Halfway there! I'm pleased to announce 10 out of our 20 selected sites have now opened to FOxTROT 4! Great job to everyone involved!👏👏👏 Leeds CTRU Jenny Seligmann Janet graham Laboratoires Pierre Fabre Merck

How to integrate NACT in locally advanced colon cancer: 👉 enroll pts in clinical trials 👉 gain experience 👉 MDT is crucial Jenny Seligmann #ESMOGI24 ESMO - Eur. Oncology

🙏🏽🙏🏽Chiara Cremolini That’s a wrap for day 1 of #ESMOGI24 Privilege to share the stage with Jeanne Tie to discuss advances in localised colon cancer foxtrot-study @DucreuxMichel

Plus a mystery LBA in this session…🤩 💥💥💥 Can’t wait #ESMO24

Tumour immune markers absolutely relevant in risk stratification for early stage colon cancer ✅ Great collaboration with Roche Diagnostics USA University of Leeds 👏👏@chrisjmwilliams published in Journal of Clinical Oncology 🤩

Neoadjuvant immunotherapy for msi-h colon and rectal cancer 👍🏻 But emerging data on complications not seen with chemo Project initiated after a pt developed bowel obstruction due to stricturing response to IO ➡️emergency resection ➡️pCR 👏James Platt & our international 🤝

Epic @chrisjmwilliams leading this 👍🏻 Very timely review post #ESMO24 neoadjuvant colon IO data! Delighted to be involved plus international 🤝 NatureRevClinOncol OncoAlert LIMRLeeds

Check out our editorial on high-risk stage II colon cancer: a call for clinicians to exercise caution when withdrawing oxaliplatin and when interpreting subanalyses sciencedirect.com/science/articl… @DrClaireGallois Jenny Seligmann

Just finished. Very interesting #MiniOral #ESMOAsia24 session in #PDAC and #Biliary that I had the pleasure to co-chair (and discuss) with Jenny Seligmann Posts coming with my thoughts 😉 Thanks Lorenza Rimassa for the 📸 🫶 ESMO - Eur. Oncology